DNA amplifications at 20q 13 and MDM2 define distinct subsets of evolved breast and ovarian tumours

British Journal of Cancer

Volumn 74, Issue 12, 1996, Pages 1984-1989

  Courjal, F ^a   Cuny, M ^a,b   Rodriguez, C ^b   Louason, G ^a   Speiser, P ^c   Katsaros, D ^d   Tanner, M M ^e   Zeillinger, R ^c   Theillet, C ^a,b  

^a INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^b CENTRE VAL D AURELLE   (France)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF TURIN   (Italy)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Amplification; Breast cancer; Oncogene

Indexed keywords

DNA; MESSENGER RNA;

AGE; ANEUPLOIDY; ARTICLE; BREAST TUMOR; CANCER GENETICS; CHROMOSOME 20Q; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; ONCOGENE; OVARY TUMOR; PRIORITY JOURNAL; SOUTHERN BLOTTING;

BREAST NEOPLASMS; CARCINOMA; CHROMOSOMES, HUMAN, PAIR 20; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; ONCOGENES; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 0030443917     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.664     Document Type: Article

References (31)

1. ADNANE J, GAUDRAY P, SIMON M, SIMONY-LAFONTAINE J, JEANTEUR P AND THEILLET C. (1989). Proto-oncogene amplification and breast cancer phenotype. Oncogene, 4, 1389-1395.
2. ADNANE J, GAUDRAY P, DIONNE CA, CRUMLEY G, JAYE M, SCHLESSINGER J, JEANTEUR P, BIRNBAUM D AND THEILLET C. (1991). BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene, 6, 659-663.
3. CORDON CARDO C, LATRE E, DROBNJAK M, OLIVA MR, POLLACK D, WOODRUFF JM, MARECHAL V, CHEN J, BRENNAN MF AND LEVINE AJ. (1994). Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res., 54, 794-799.
4. CHOMCZINSKI P AND SACCHI N. (1987). Single step method of RNA isolation by acid guanidium thiocyanale phenol chloroform extrraction. Ann. Biochem., 162, 156-159.
5. ESCOT C, THEILLET C, LIDEREAU R, SPYRATOS F, CHAMPÈME MH, GEST J AND CALLLAHAN R. (1986). Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc. Natl. Acad. Sci. USA, 83, 4834-4838.
6. FAKHARZADEH SS, TRUSKO SP AND GEORGE DL. (1991). Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor line. EMBO J., 10, 1565-1569.
7. FINLAY CA. (1993). The mdm-2 oncogcne can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol., 13, 301-306.
8. FLORENES VA, MAELANDSMO GM, FORUS A, ANDREASSEN A, MYKLEBOST O AND FODSTAD O. (1994). MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status (see comments). J. Natl Cancer Inst., 86, 1297-1302.
9. GUAN XY, MELTZER P, DALTON WS AND TRENT JM. (1994). Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection. Nature Genet., 8, 155-161.
10. HABUCHI T, KINOSHITA H, YAMADA H, KAKEHI Y, OGAWA O, WU WJ, TAKAHASHI R, SUGIYAMA T AND YOSHIDA O. (1994). Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification (see comments). J. Natl Cancer Inst., 86, 1331-1335.
11. HAWKINS DM AND KASS GV. (1982). Automatic interaction detection. In Applied Multivariate Analysis. Hawkins DG (ed.) pp. 1-10. Cambridge University Press: Cambridge.
12. ISOLA J, KALLIONIEMI O-P, CHU LW, FUQUA SA, HILSENBECK SG, OSBORNE CK AND WALDMAN FM. (1995). Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am. J. Pathol., 147, 905-911.
13. KALLIONIEMI O-P, KALLIONIEMI A, SUDAR D, RUTOVITZ D, GRAY JW, WALDMAN F AND PINKEL D. (1993). Comparative genomic hybridization: a rapid new method for detecting and mapping DNA amplification in tumors. Semin. Cancer Biol., 4, 41-46.
14. KALLIONIEMI A, KALLIONIHMI O-P, PIPER J, TANNER M, STOKKE T, CHEN L, SMITH HS, PINKEL D, GRAY JW AND WALDMAN FM. (1994). Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc. Natl Acad. Sci. USA, 91, 2156-2160.
15. LAMMIE GA, FANTL V, SMITH R, SCHUURING E, BROOKES S, MICHALIDES R, DICKSON C, ARNOHD A AND PETERS G. (1991). D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene, 6, 439-444.
16. LEACH FS, TOKINO T, MELTZER P, BURRELL M, OLINER JD, SMITH S, HILL DE, SIDRANSKY D, KINZLER KW AND VOGELSTEIN B. (1993). p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res., 53, 2231-2234.
17. MCCANN AH, KIRLEY A, CARNEY DN, CORBALLY N, MAGEE HM, KEATlNG G AND DERVAN PA. (1995). Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br. J. Cancer, 71, 981-985.
18. MELTZER PS, JANKOWSKI SA, DAL CIN P, SANDBERG AA, PAZ IB AND COCCIA MA. (1991). Identification and cloning of a novel amplified DNA sequence in human malignant fibrous histiocytoma derived from a region of chromosome 122 frequently rearranged in soft tissue tumors. Cell Growth Differ., 2, 495-501.
19. MOMAND J, ZAMBETTI GP, OLSON DC, GEORGE D AND LEVINE AJ. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69, 1237-1245.
20. OLINER JD, KINZLER KW, MELTZER PS, GEORGE DL AND VOGELSTEIN B. (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358, 80-83.
21. OLINER JD, PIETENPOL JA, THIAGALINGAM S, GYURIS J, KINZLER KW AND VOGELSTEIN H. (1993). Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 362, 857-860.
22. PATTERSON H, GILL S, FISHER C, LAW MG, JAYATILAKE H, FLETCHER CD, THOMAS M, GRIMER R, GUSTERSON BA AND COOPER CS. (1994). Abnormalities of the p53 MDM2 and DCC genes in human Leiomyosarcomas. Br. J. Cancer. 69, 1052-1058.
23. PREUDHOMME C, QUESNEL B, VACHEE A, LEPELLEY P, COLLYN DH, WATTEL E AND FENAUX P. (1993). Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes. Leukemia. 7, 1291-1293.
24. QUESNEL B, PREUDHOMME C, OSCIER D, LEPELLEY P, COLLYN H, FACON T, ZANDECKI M AND FENAUX P. (1994a). Overexpression of the MDM2 gene is found in some cases of haematological malignancies. Br. J. Haematol., 88, 415-418.
25. QUESNEL B, PREUDHOMME C, FOURNIER J, FENAUX P AND PEYRAT JP. (1994b). MDM2 gene amplification in human breast cancer. Eur. J. Cancer, 30A, 982-984.
26. SAMBROOK J, FRITSCH E AND MANIATIS T. (1989). Molecular Cloning: a Laboratory Manual. Cold Spring Harbor Laboratory Press: New York.
27. SLAMON DJ, GODOLPHIN W, JONES LA, HOLT JA, WONG SG, KEITH DE, LEVIN WJ, STUART SG, UDOVE J, ULLRICH A AND PRESS MF. (1989). Studies of the HER-2 neu proto-oncogene in human breast and ovaraian cancer. Science. 244, 707-712.
28. STENMAN G, SAHLIN P, MARK J, CHAGANTI RS, KINDBLOM LG AND AMAN P. (1993). The 12q13 q15 translocation breakpoints in pleomorphic adenoma and clear-cell sarcoma of tendons and aponeuroses are different from that in myxoid liposarcoma. Genes Chromosom. Cancer. 7, 178-180.
29. TANNER M, TIRKKONEN M, KALLIONIEMI A, COLINS C, STOKKE T, KARHU R, KOWBNEL D, SHARADRAVAN F, HINTZ M, KUO W-L, WALDMAN F, ISOLA J, GRAY J AND KALLIONIEMI O-P. (1994). Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. Cancer Res., 54, 4257-4260.
30. TANNER MM, TIRKKONEN M, KALLIONIEMI A, HOLLI K, COLLINS C, KOWBEL D, GRAY JW, KALLIONIEMI O-P AND ISOLA J. (1996). Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clinical Cancer Res., 1, (in press).
31. WABER PG, CHEN J AND NISEN PD. (1993). Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res., 53, 6028-6030.